About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Deep Science Ventures and AbbVie to create companies to target inflammatory diseases

Replay receives $1.5M grant for hypoimmunogenic technology platform

Localizing BRCA gene mutations to better treat ovarian cancer

Biomemory raises €5M to advance DNA digital data storage solution

New function of CRISPR gene scissors discovered

Beyond Biotech podcast 24: Concarlo Therapeutics, Eversana, Carl Borrebaeck, SOTIO Biotech

ADVERTISEMENT

XtalPi and CK Life Sciences partner on tumor vaccine R&D

AI works on artificial DNA for future drug development

BC Platforms partners on AI-driven EU cancer data project

FDA gives IND approval for Ascletis Covid drug

Concern as study says new covid sub-variant is resistant to all therapeutic antibodies

ADVERTISEMENT